Breast cancer is the leading cause of female cancer deaths. Bone is the commonest
site of breast cancer metastasis (40%) will be in the bone. Bone Morphogenetic Protein
(BMP) antagonists have been shown to stimulate glycolysis as well as epithelial mesenchymal
transition (EMT), which increases the motility of malignant cells and contributes
to the development of metastases. The role of GREM1 in HER2+ breast cancer progression
remains an under-researched yet promising area of study.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Abstracts for BASO Medical Student Oral Prize Presentation at the BASO Trainees/ Skills Day: 19th November 2022 3.
Identification
Copyright
© 2022 Published by Elsevier Inc.
